SABCS 2017: Tamoxifen Plus Ovarian Function Suppression Regimen for Early Breast Cancer
An updated report of the SOFT trial found that the addition of an ovarian function suppression (OFS) treatment to tamoxifen improved disease-free survival in premenopausal women with hormone receptor–positive early breast cancer versus tamoxifen alone. Gini Fleming, MD, of the University of Chicago, presented updates from this randomized comparison trial at the 2017 San Antonio Breast Cancer Symposium (SABCS; Abstract GS4-03).
After a median follow-up of 8 years, investigators analyzed disease-free survival rates for 3047 patients. Patients were stratified by use of prior chemotherapy and randomized equally to receive tamoxifen or tamoxifen plus OFS.
Patients who received the doublet therapy showed a significantly higher disease-free survival rate of 83.2% versus 78.9% for patients in the single-treatment arm. Prior chemotherapy did not significantly affect the rates of disease-free survival. Differences between therapies showed a 5.3% change in patients who underwent prior chemotherapy versus a 3.2% change in those who did not.
Although patients experienced higher disease-free survival rates in the combination therapy group, they also experienced higher rates of grade 3 adverse events compared with women treated with tamoxifen (32% vs. 25%). The investigators will conduct additional follow-up and develop further information regarding the safety and efficacy of OFS for late recurrence and overall survival results.